We will finalize this series on where we should go, and what’s next in terms of immunotherapy in the adjuvant setting, by looking into the two other aspects that we need to consider when we discuss the factthat there is no overall survival benefit nor are there data on the overall survival benefit for patients treated with immunotherapy in the adjuvant setting.
Health Professionals
Study reveals a unique vulnerability in melanoma patients with neurofibromin 1 mutations
Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a new study shows.
Immune markers in blood could predict toxicity and treatment response to immunotherapy in melanoma
New research identifies blood-based B cell and antibody signatures that could guide safer treatment for patients receiving immunotherapy.
Study Shows that Existing Drug Class May Help Patients with Skin Cancer that Resists Standard Treatments
ncreased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a new study shows.